Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Rhea-AI Summary

Outlook Therapeutics fireside chat details

On September 28, 2021, at 2:00 PM ET, C. Russell Trenary, President and CEO of Outlook Therapeutics (Nasdaq: OTLK), will participate in a live fireside chat during the Cantor Fitzgerald Virtual Global Healthcare Conference. This event includes opportunities for virtual one-on-one meetings with the investor community. The chat will be accessible via a live webcast on the company's Investors page and available for 90 days post-event.

Outlook Therapeutics aims to develop ONS-5010 as the first FDA-approved ophthalmic formulation of bevacizumab.

Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET

ISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat hosted by Kristen Kluska, Director, Equity Research at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 2:00 PM ET.

In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Outlook Therapeutics website (outlooktherapeutics.com) and accessible for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is the date and time of the Outlook Therapeutics fireside chat?

The fireside chat is scheduled for September 28, 2021, at 2:00 PM ET.

Who is participating in the fireside chat at the Cantor Fitzgerald conference?

C. Russell Trenary, President and CEO of Outlook Therapeutics, will participate in the chat.

How can I access the live webcast of the Outlook Therapeutics fireside chat?

The live webcast can be accessed on the Investors page of the Outlook Therapeutics website.

What is ONS-5010 and its significance for Outlook Therapeutics?

ONS-5010 is an ophthalmic formulation of bevacizumab aimed for retinal indications, which Outlook Therapeutics hopes to be the first FDA-approved version.

Will there be opportunities to meet with Outlook Therapeutics management during the conference?

Yes, there will be virtual one-on-one meetings available for registered investor community members.